NCT05811949View on ClinicalTrials.gov

Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

October 11, 2022

Study Completion Date

June 7, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Dimethyl Fumarate 240 MG [Tecfidera]

DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.

Trial Locations (1)

98124

"IRCCS Centro Neurolesi Bonino-Pulejo", Messina

All Listed Sponsors
lead

IRCCS Centro Neurolesi Bonino Pulejo

OTHER

NCT05811949 - Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis. | Biotech Hunter | Biotech Hunter